Evidence map›Paper›PMID 32019171›Full record

ReviewMicroorganisms2020

Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Despoina Koulenti, Elena Xu, Andrew Song, Isaac Yin Sum Mok, Drosos E Karageorgopoulos, Apostolos Armaganidis, Sotirios Tsiodras, Jeffrey Lipman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Antibacterial action mechanisms and mode of trypsin inhibitors: a systematic review.Journal of enzyme inhibition and medicinal chemistry · 2022
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Despoina KoulentiUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Elena XuUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Andrew SongUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Isaac Yin Sum MokUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
Drosos E Karageorgopoulos4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece.
Apostolos Armaganidis2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece.
Sotirios Tsiodras4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece.
Jeffrey LipmanUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial agents are currently the mainstay of treatment for bacterial infections worldwide. However, due to the increased use of antimicrobials in both human and animal medicine, pathogens have now evolved to possess high levels of multi-drug resistance, leading to the persistence and spread of difficult-to-treat infections. Several current antibacterial agents active against Gram-positive bacteria will be rendered useless in the face of increasing resistance rates. There are several emerging antibiotics under development, some of which have been shown to be more effective with an improved safety profile than current treatment regimens against Gram-positive bacteria. We will extensively discuss these antibiotics under clinical development (phase I-III clinical trials) to combat Gram-positive bacteria, such as

Indexed as

clinical trialsdefensin mimeticsdihydrofolate reductase inhibitorsemerging anti gram-positive antibioticsketolidesmulti-drug resistance organismsoxazolidinonesquinolonestopoisomerase II inhibitorsβ-lactams

Identifiers

PMID32019171
PMCPMC7074912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.